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Open accAbstract Background: This multicentre, randomised, open label, phase II/III study aimed to
investigate the potential beneﬁt of adding risedronate (R) to docetaxel (D) in patients with
metastatic Castration Resistant Prostate Cancer (CRPC).
Patients and methods: CRPC patients with bone metastasis were randomly assigned to receive
D 75 mg/m2 every 3 weeks and prednisone as ﬁrst line chemotherapy, with or without R 30 mg
oral once daily. The primary end-point was time to progression (TTP). A composite end-point
of objective progression by RECIST criteria, PSA progression, or pain progression, whichever
occurred ﬁrst, was applied. The study had 80% power to detect an improvement of 30% in
median TTP in the DR group (two-sided a = 0.05).
Results: Five hundred and ninety-two men (301 D versus 291 DR) were randomised. TTP was
7.4 [D] versus 6.5 [DR] months (p = 0.75). PSA and pain response rates were similar, 66.3%14
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2994 H.J. Meulenbeld et al. / European Journal of Cancer 48 (2012) 2993–3000[D] versus 65.9% [DR] and 27.9% [D] versus 31.2% [DR], respectively. Median overall
survival (OS) was 18.4 [D] versus 19.2 [DR] months (p = 0.33). There were no differences in
toxicity.
Conclusion: The addition of the third generation bisphosphonate, risedronate, in the setting of
effective ﬁrst line docetaxel based chemotherapy did not increase efﬁcacy, as indicated by the
lack of improvement in TTP, OS, PSA- and pain response.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. 1. Introduction
Approximately 80% of patients with advanced Cas-
tration Resistant Prostate Cancer (CRPC) develop bone
metastases that often lead to severe bone pain, hyper-
calcaemia and skeletal-related events (SREs).1,2 Despite
the osteoblastic appearance of prostate cancer bone
metastases, there is increasing evidence that most metas-
tases are characterised by excessive activity of both oste-
oblasts and osteoclasts.3–6
Bisphosphonates are potent inhibitors of osteoclast-
mediated bone resorption. In CRPC zoledronic acid
has shown to delay the onset and the incidence of
SREs.2,7 Zoledronic acid was approved and quickly
became established as the standard of care in the United
States in 2002. In several European countries the intro-
duction of zoledronic acid took a slower pace since the
delay of SREs was considered a weak primary end-point
to justify expensive medication. In 2004, the treatment
paradigm of metastatic CRPC changed after two land-
mark trials,8,9 demonstrated for the ﬁrst time a survival
beneﬁt in patients with metastatic CRPC utilising doce-
taxel based chemotherapy, setting a new standard of
care for patients with CRPC. With the results of these
studies the question arose in Europe what the role of bis-
phosphonates was relative to the initiation of eﬀective
chemotherapy.
An emerging body of preclinical evidence indicate
that bisphosphonates also exhibit direct anti-tumour
activity.10–12 In vitro data have shown that bisphospho-
nates directly inhibit breast and prostate carcinoma cell
invasion.13,14
However, clinical data of bisphosphonates, on anti-
tumour eﬃcacy are limited, and provide conﬂicting evi-
dence. Risedronate is an oral third generation pyridinyl
bisphosphonate, which reduces bone turnover and
reduces osteoclast-mediated resorption.15
Data from animal models have shown that risedro-
nate and docetaxel act synergistically to decrease
tumour burden of established bone metastases from
breast cancer cells.16
Since both in vivo and in vitro studies have shown syn-
ergistic action of zoledronate and taxanes,17–19 there is a
rationale to conduct this study to evaluate the eﬃcacy
and safety proﬁle of adding risedronate to docetaxel in
patients with CRPC with bone metastases.2. Materials and methods
2.1. Patients
This randomised, open label, phase II/III trial was
undertaken at 45 centres in the Netherlands and one
in Norway. Patients had histologically proven prostate
cancer with progression during prior castration and cas-
tration levels of testosterone. Progressive disease was
deﬁned as PSA progression documented by at least
two consecutive increases relative to a reference value
measured at least a week apart. The initial protocol
included all patients with metastatic CRPC, but during
the early phase of the trial, the eligibility criteria were
modiﬁed so that only patients with bone metastases
were to be included. Patients without bone metastases
at randomisation were excluded from the eﬃcacy analy-
sis. Eligible patients were P18 years, with an Eastern
Cooperative Oncology Group (ECOG) performance
status 62, and adequate haematological, hepatic and
renal function. Patients with disease related pain at
entry must have been on a stable analgesic regimen
P1 week prior to registration. Prior antiandrogen with-
drawal followed by progression had to have taken place
at least 4 weeks prior to randomisation (6 weeks for
bicalutamide). LHRH analogues were continued, unless
patients were surgically castrated. Any prior or concom-
itant use of bisphosphonates was excluded. Patients who
had received radiotherapy within 4 weeks before enrol-
ment, CNS involvement, or other serious illness (includ-
ing secondary cancer) were excluded.
The study was conducted according to the Declara-
tion of Helsinki and in compliance with Good Clinical
Practice and local ethical and legal requirements. Writ-
ten informed consent was obtained from all participants.
2.2. Study design
Patients were randomly assigned to receive docetaxel
75 mg/m2 intravenously, every 3 weeks and prednisone
5 mg bid, with or without risedronate 30 mg oral od.
Chemotherapy was continued until progression, unac-
ceptable toxicity, or withdrawal of consent for a maxi-
mum of 10 cycles. In the DR group, R and prednisone
was continued until progression. At the time of progres-
sion, further treatment was at the discretion of the
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arm were oﬀered R. Treatment delays of up to two
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analgetics (I + II)
62% 68%
Mild opiates (III) 8% 9%
Opiates (IV + V) 23% 18%
NA 7% 5%
PS, performance score; NA, not applicable; PSA, prostate speciﬁc
antigen; PPI, present pain intensity score.2.3. Follow-up and outcomes
Pre-treatment evaluations included a medical history,
ECOG performance status, physical examination, labo-
ratory screening, serum PSA and testosterone concen-
tration, chest X-ray or CT scan, abdominal CT scan
and a bone scan. Pain and analgesic consumption was
assessed at baseline, every three weeks, at end of study
and then every month until pain progression or further
anti-tumour therapy. Pain was assessed with Present
Pain Intensity (PPI) scale from the McGill–Melzack
questionnaire.20 Physical examinations and blood tests,
including PSA, were repeated before each infusion of
docetaxel and at the end of treatment, and then every
month during 6 months and every 2 months thereafter
until PSA progression or further anti-tumour therapy.
Bone scans were performed before study entry, after
week 30, to conﬁrm a response, and at study discontin-
uation. In patients with measurable disease, CT scans
were repeated at intervals of 9 weeks, when clinical pro-
gression was suspected, and at end of chemotherapy. All
assessments were repeated to conﬁrm a response at least
4 weeks later.
The primary end-point of the phase II part was the
rate of objective (PSA) responses to treatment. Per an
attained phase III design, at least 26 responses out of
69 evaluable patients must have been observed in the
experimental arm, to continue the study as a random-
ised phase III study. In the phase III part the primary
end-point was TTP. A composite end-point of objective
progression by Response Evaluation Criteria in Solid
Tumours (RECIST)21 criteria, PSA progression, or pain
progression, whichever occurred ﬁrst, was applied. PSA
progression was deﬁned as an increase of P25% over
nadir PSA concentration provided that the increase in
the absolute PSA value was P5 ng/ml for men without
PSA response, orP50% over nadir for PSA responders.
Pain progression was deﬁned as an increase in median
PPI score of P1 point from the nadir, increase in anal-
gesics class compared to nadir, or requirement for palli-
ative radiotherapy.
Secondary end-points included PSA response, dura-
tion of PSA response and pain response. PSA response
was deﬁned by P50% decline in serum PSA concentra-
tion compared to baseline in patients with a baseline
value of P20 lg/L, conﬁrmed at least 4 weeks later.
Pain response was deﬁned as P2 point reduction from
baseline median PPI score, without increase in analgesic
class, or a decrease in analgesic class without an increase
in PPI score, maintained for 2 consecutive evaluations at
least three weeks apart. Other secondary end-points
were toxicity, response by RECIST and overall survival(OS). Toxicity was assessed before each treatment cycle
and graded according to the National Cancer Institute
Common Terminology Criteria for adverse events
(version 2).
On the basis of emerging guidelines recommending
the delivery of 12 weeks of treatment before adjustment
of therapy for metastatic CRPC,22 an amendment was
made to the trial protocol after 115 patients had been
enrolled to ensure that PSA increase only did not qualify
for progression within the ﬁrst four cycles of treatment.
2.4. Statistical analysis
This study consisted of a phase II and a phase III
part. In the randomised phase II part, Simon’s two-stage
minimax design was used,23 where the experimental
treatment would be declared of insuﬃcient activity if
25 or fewer PSA responses would be observed out of
69 evaluable patients in the experimental arm with
90% power at a = 0.1. If this criterion was met, the study
was extended into phase III, with TTP as the primary
end-point.
A sample size of 589 patients was required (456
events), to detect an improvement of 30% in median
TTP in the DR group relative to the D group
(HR = 0.77) with 80% power, with a two-sided signiﬁ-
Table 2
Consort diagram.
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in the D group. Patients were randomised between two
groups (1:1 ratio), stratifying according to measurable
versus non-measurable disease and median PPI at base-
line (P2 versus <2). TTP, OS and duration of response
were analysed using the Kaplan–Meier method, with log
rank comparison. Response rates were calculated as per-
centage of evaluable patients along with binomial conﬁ-
dence intervals. TTP was calculated from the date of
randomisation to the date of RECIST, PSA, or painprogression, whichever occurred ﬁrst. Patients without
progression at death or last follow-up were censored.
TTP was also calculated for the composite end-points
separately, censoring patients for a particular type if
they experienced another type ﬁrst.
Safety analyses included all randomised men. Hazard
ratios (HR) and 95% conﬁdence intervals (95% CIs)
were calculated with a Cox proportional hazards model.
A separate analysis for TTP was performed excluding
the group of patients with disease progression only
Fig. 1. Time to progression. D, docetaxel; DR, docetaxel and
risedronate; TTP, time to progression; HR, hazard ratio; CI,
conﬁdence interval.
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treatment. SAS software (version 9.2) and R (version
2.14.0) were used for all analyses.
3. Results
3.1. Patients and treatment
From January 2004 to April 2010, 592 patients were
enrolled and randomly assigned to one of the study arms
(301 D and 291 DR). Patient demographics and baseline
characteristics were well balanced between the two
groups (Table 1). There were 23 patients without bone
metastases enrolled before the amendment to require
evidence of bone metastases. Exposure to docetaxel
was similar between the two groups, with a median of
nine cycles. Most discontinuations were because of end
of protocol treatment (277 of 592; 47%) and were bal-
anced between the two groups (Table 2). The median
follow-up was 42 months.
3.2. Eﬃcacy
At data cut oﬀ 1st July 2011 about 86% of the
patients in both groups had investigator determined
progressive disease (Table 3). Upon progression 97
patients in the D alone arm were treated with R. Median
TTP (a composite end-point) was 7.4 versus 6.5 months
(HR 1.04; 95% CI 087–1.24) for D and DR, respectively
(Fig. 1). Furthermore, there were no diﬀerences in time
to progression (TTP) by the separate end-points of pain
progression, PSA progression and time to objective pro-
gression according to RECIST criteria (Fig. 2). The
adjusted analysis excluding the 2 patients (both in the
D group) with disease progression only based on PSA
increase during the ﬁrst four cycles of treatment, showed
a median TTP of 7.5 versus 6.5 months for the D and
DR group respectively. The Kaplan–Meier analysis
showed no diﬀerence in OS. Median OS was
18.4 months for D and 19.2 months for DRTable 3







Total no. of patients with
progression
248 (87%) 242 (86%)
During docetaxel 91 (37%) 106 (44%)
Within 3 months after
docetaxel
67 (27%) 73 (30%)
Between 3 and 6 months after
docetaxel
54 (22%) 29 (12%)
Later than 6 months after
docetaxel
33 (13%) 31 (13%)
Progression, but date end of
chemotherapy missing
3 (1%) 3 (1%)(HR = 1.09; p = 0.33; Fig. 3). The objective response
according to RECIST, pain response and/or PSA
response were similar in both groups (Table 4). Eighteen
patients (9 D versus 9 DR) required palliative radiother-
apy within 3 months after last chemotherapy.3.3. Toxicity
No signiﬁcant diﬀerences were observed between the
D and DR arm in the incidence grade 3/4 toxicity.
The most frequent non-haematological grade 3 or
higher adverse events were neurotoxicity, diarrhoea
and nausea (Table 5). The information on the frequency
of grade 3–4 haematological toxicity is limited since
weekly blood counts were not mandatory. Neutropenic
fever was observed in 5% versus 8% of the patients in
the D and DR group respectively. No cases of osteone-
crosis of the jaw were observed. Of the 436 deaths, 215
and 221 deaths occurred in the D group and DR group,
respectively. Twelve patients (6 DR and 6 D) died within
30 days after the last cycle of docetaxel treatment. The
most frequent cause of death was related to disease pro-
gression. There were 2 treatment related deaths (all in
the D group) 1 due to neutropenic sepsis and 1 patient
died from sepsis during docetaxel treatment but was
not neutropenic. During the follow-up phase similar
number of patients in the D and DR group received sec-
ond line antineoplastic therapy (33% D versus 36% DR).4. Discussion
When bisphosphonates, such as zoledronic acid, were
introduced in Europe in the early 2000s, to delay SREs
Fig. 2. Kaplan–Meier curves for separate progression end-points. (A) Pain progression; (B) progression according to RECIST; (C) PSA
progression. D, docetaxel; DR, docetaxel and risedronate; TTP, time to progression; HR, Hazard ratio; CI, conﬁdence interval.
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the phase III docetaxel studies that showed survival ben-
eﬁt.8,9 In Europe many patients did not yet routinely
receive zoledronic acid until they had reached a mCRPC
status. The obvious question therefore was whether bis-
phosphonates would provide an additional beneﬁt at the
time of initiation of eﬀective docetaxel chemotherapy.
There are clinical and preclinical data suggesting that
bisphosphonates have osteoclast-independent eﬀects
that can be associated with an anti-tumour eﬀect.
Data from animal models have shown that risedro-
nate and docetaxel act synergistically to protect bone
and decrease tumour burden of established bone metas-
tases from breast cancer cells.16 The current study is the
ﬁrst prospective study evaluating the eﬀectiveness of the
third generation bisphosphonate risedronate incombination with docetaxel in CRPC. Our results dem-
onstrate that the addition of risedronate to docetaxel,
although well tolerated, has no impact on disease pro-
gression and OS. We found neither reduction in pain
scores with the addition of risedronate to docetaxel in
our study. The median OS in this study is comparable
to previous studies with docetaxel based chemotherapy.
We found a higher incidence of neutropenic fever in
our study compared to previous studies.8,9 This might
be attributable to diﬀerences in patient populations.
As a result of the established OS beneﬁt and the previ-
ously reported low incidence of neutropenic fever, in
recent years there may have been a shifting threshold
in treating more frail patients with more advanced dis-
ease with an associated higher risk of neutropenic
complications.
Fig. 3. Overall survival. D, docetaxel; DR, docetaxel and risedronate;
OS, overall survival; HR, Hazard ratio; CI, conﬁdence interval.
Table 4
Response rate and duration of response.
D DR Hazard ratio
(95% CI)
Tumour assessment
Response ratea 20.8% 25.1%
Duration of response (months) 9.4 9.5 1.05 (0.70–1.57)
PSA assessment
Response ratea 66.3% 65.9%
Duration of response (months) 8.0 8.1 0.94 (0.73–1.20)
Pain assessment
Response ratea 27.9% 31.2%
Duration of response (months) 5.5 3.4 1.27 (0.84–1.92)
D, docetaxel; DR, docetaxel and risedronate; CI, conﬁdence interval.
a Determined only for subjects with at baseline measurable disease,
PSA P20 ng/ml, or median PPI >2 on McGill–Melzack scale,
respectively.
Table 5
Adverse events. D, docetaxel; DR, docetaxel and risedronate.









Any adverse event 289 (96%) 163 (54%) 284 (98%) 161 (55%)
Febrile
neutropenia
15 (5%) 23 (8%)
Diarrhoea 86 (29%) 9 (3%) 96 (33%) 6 (2%)
Neurotoxicity 139 (46%) 11 (4%) 149 (51%) 10 (3%)
Nausea 101 (34%) 3 (1%) 112 (38%) 3 (1%)
Hypocalcaemia 0 (0%) 0 (0%) 3 (1%) 1 (0.3%)
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increase toxic eﬀects associated with standard docetaxel
and could be safely administered.
Four parameters should be considered when selecting
a bisphosphonate: eﬃcacy, compliance, adherence and
safety. The choice of risedronate in our study was foran oral rather than an intravenous route of administra-
tion. Risedronate is the most potent oral nitrogen con-
taining bisphosphonate available and there is strong
pre-clinical evidence of a possible eﬃcacy of the drug
in skeletal metastases.15,24 Patient’s adherence to drug
intake was monitored at each study visit by directly
interviewing patients if they had been taking their pre-
scribed medication, both by the treating physicians
and at the time of collecting the patient diaries by the
oncology nurses.
A potential confounder of this trial was its open-label
design. Pain scores, analgesic use and quality of life are
diﬃcult to objectively measure and may be confounded
by the absence of blinding and could have potentially
introduced observer and patient biases. However, since
the study is entirely negative we do not believe that
the results have been subjected by bias, as we found nei-
ther diﬀerences in palliative outcome measures, nor an
improvement in TTP and OS by adding risedronate to
docetaxel.
In patients with hormone-sensitive prostate cancer
and bone metastases, sodium clodronate, an oral ﬁrst
generation bisphosphonate, may improve OS when
given in addition to standard hormone therapy.25 Thus
far this is the only trial that has shown such beneﬁt in
patients with prostate cancer. The eﬀects of zoledronic
acid are currently being evaluated in patients with met-
astatic hormone-sensitive prostate cancer who are
receiving androgen deprivation therapy in the Cancer
and Leukaemia Group B (CALGB) 90202 trial. Results
from this trial may provide further insights into the
potential beneﬁts of bisphosphonates in the setting of
hormone-sensitive disease.26
Our study though, demonstrates that the addition of
the third generation risedronate to docetaxel in patients
with CRPC with bone metastases, although well toler-
ated, has no eﬀect on TTP, PSA- and pain response and
OS. Therefore, the addition of this bisphosphonate to
docetaxel based chemotherapy cannot be recommended.Conﬂict of interest statement
This work was supported by Sanoﬁ-Aventis, Gouda,
The Netherlands. Ronald de Wit has consultant/advi-
sory relationships with Sanoﬁ-Aventis and has received
honoraria and research funding from Sanoﬁ-Aventis.
He has no employment or leadership position, stock
ownership, research funding, expert testimony or other
remuneration disclosures. The other authors have no
conﬂict of interest.Acknowledgements
First of all we thank all patients who agreed to partic-
ipate in this trial. Funding was provided by Grants from
Sanoﬁ-Aventis.
3000 H.J. Meulenbeld et al. / European Journal of Cancer 48 (2012) 2993–3000References
1. Saad F, Lipton A. Clinical beneﬁts and considerations of
bisphosphonate treatment in metastatic bone disease. Semin Oncol
2007;34(Suppl. 4):S17–23.
2. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-
controlled trial of zoledronic acid in patients with hormone-
refractory metastatic prostate carcinoma. J Natl Cancer Inst
2002;94:1458–68.
3. Berruti A, Dogliotti L, Tucci M, et al. Metabolic bone disease
induced by prostate cancer: rationale for the use of bisphospho-
nates. J Urol 2001;166:2023–31.
4. Clarke NW, McClure J, George NJ. Morphometric evidence for
bone resorption and replacement in prostate cancer. Br J Urol
1991;68:74–80.
5. Saad F, Clarke N, Colombel M. Natural history and treatment
of bone complications in prostate cancer. Eur Urol 2006;49:
429–40.
6. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal
complications in patients with bone metastatic prostate cancer and
hormone refractory disease: predictive role of bone resorption and
formation markers evaluated at baseline. J Urol 2000;164:
1248–53.
7. Saad F, Gleason DM, Murray R, et al. Long-term eﬃcacy of
zoledronic acid for the prevention of skeletal complications in
patients with metastatic hormone-refractory metastatic prostate
carcinoma. J Natl Cancer Inst 2003;95:879–82.
8. Tannock F, de Wit R, Berry WR, et al. Docetaxel plus prednisone
or mitoxantrone plus prednisone for advanced prostate cancer. N
Engl J Med 2004;351:1502–12.
9. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and
estramustine compared with mitoxantrone and prednisone for
advanced refractory prostate cancer. N Engl J Med 2004;351:
1513–20.
10. Morgan G, Lipton A. Antitumor eﬀects and anticancer applica-
tions of bisphosphonates. Semin Oncol 2010;37(Suppl. 2):S30–40.
11. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-
controlled trial of clodronate in patients with primary operable
breast cancer. J Clin Oncol 2002;20:3219–24.
12. Coleman RE, Winter MC, Cameron D, et al. The eﬀects of adding
zoledronic acid to neoadjuvant chemotherapy in tumour response:
exploratory evidence for direct anti-tumour activity in breast
cancer. Br J Cancer 2010;102:1099–2005.
13. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates
inhibit breast and prostate carcinoma cell invasion, an early event
in the formation of bone metastases. Cancer Res 2000;60(11):
2949–54.14. Lee MV, Fong EM, Singer FR, et al. Bisphosphonate treatment
inhibits the growth of prostate cancer cells. Cancer Res
2001;61(6):2602–8.
15. Dunn CJ, Goa KL. Risedronate: a review of its pharmacological
properties and clinical use in resorptive bone disease. Drugs
2001;61:685–712.
16. van Beek ER, Lowik CW, van Wijngaarden J, et al. Synergistic
eﬀect of bisphosphonate and docetaxel on the growth of bone
metastasis in an animal model of established metastatic bone
disease. Breast Cancer Res Treat 2009 Nov;118(2):307–13.
17. Karabulut B, Erten C, Gul MK, et al. Docetaxel/zoledronic acid
combination triggers apoptosis synergistically through downreg-
ulating antiapoptotic Bcl-2 protein level in hormone-refractory
prostate cancer cells. Cell Biol Int 2009;33:239–46.
18. Brubaker KD, Brown LG, Vessella RL, et al. Administration of
zoledronic acid enhances the eﬀects of docetaxel on growth of
prostate cancer in the bone environment. BMC Cancer 2006;6:15.
19. Ullen A, Lennartsson L, Harmenberg U, et al. Additive/synergis-
tic antitumoral eﬀects on prostate cancer cells in vitro following
treatment with a combination of docetaxel and zoledronic acid.
Acta Oncol 2005;44:644–50.
20. Melzack R. The McGill pain questionnaire: major properties and
scoring methods. Pain 1975;1:277–99.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors: European
Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst 2000;92:205–16.
22. Scher HI, Halabi S, Tannock F, et al. Design and end points of
clinical trials for patients with progressive prostate cancer and
castrate levels of testosterone: recommendations of the Prostate
Cancer Clinical Trials Working Group. J Clin Oncol
2008;26:1148–59.
23. Simon R. Optimal two-stage designs for phase II clinical trials.
Control Clin Trials 1989;10:1–10.
24. Sasaki A, Boyse BF, Story B, et al. Bisphosphonate risedronate
reduces metastatic human breast cancer burden in bone in nude
mice. Cancer Res 1995;55:3551–7.
25. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR.
Adjuvant therapy with oral sodium clodronate in locally advanced
and metastatic prostate cancer: long-term overall survival results
from the MRC PR04 and PR05 randomised controlled trials.
Lancet Oncol 2009;10:872–6.
26. Saad F, Colombel M. Management of castration resistant prostate
cancer bisphosphonates and emerging therapies. Expert Rev
Anticancer Ther 2010;10:1991–2002.
